Efficacy and Safety of Rituximab in Korean Patients with Refractory Inflammatory Myopathies

BACKGROUND: Rituximab (RTX), a monoclonal antibody that selectively binds to CD20+ B cells, showed favorable outcomes in patients with idiopathic inflammatory myopathies (IIM) in small case series, but the evidence is still not enough. Our goal was to determine the efficacy and safety of RTX for Kor...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahn, Ga Young, Suh, Chang-Hee, Kim, Yong-Gil, Park, Yong-Beom, Shim, Seung Cheol, Lee, Sang-Heon, Lee, Shin-Seok, Bae, Sang-Cheol, Yoo, Dae Hyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521958/
https://www.ncbi.nlm.nih.gov/pubmed/32989931
http://dx.doi.org/10.3346/jkms.2020.35.e335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521958/
https://www.ncbi.nlm.nih.gov/pubmed/32989931
http://dx.doi.org/10.3346/jkms.2020.35.e335

Ejemplares similares